Interferon-γ Release Assay (IGRA) Negativity Rates after TB-Treatment in HIV-infected Individuals

Project

Interferon-γ Release Assay (IGRA) Negativity Rates after TB-Treatment in HIV-infected Individuals

Automatically Closed · 2012 until 2013

Hoffmann Matthias, Ruhwald Morten, Hasse Barbara, Fenner Lukas, Schmid Patrick, Vernazza Pietro

Type

Clinical Studies

Range

Multicentric, KSSG as main centre

Units

Division of Infectious Diseases, Infection Prevention and Travel Medicine

Status

Automatically Closed

Start Date

2012

End Date

2013

Financing

Others

Partner

Swiss HIV Cohort Study (SHCS)

Brief description/objective

Background:
Interferon-γ Release assays (IGRA) have partly replaced conventional tuberculin skin tests (TST) in the recent years due to their higher specificity and standardised test procedures including a positive / negative control. Nevertheless it is currently unknown if IGRA reverse to negative results and in what time after successful TB-treatment in HIV-infected persons.

Study Aims:
The aim of the study is to evaluate the rate of positive / negative / indeterminate IGRA test results and absolute Mycobacterium tuberculosis-specific cytokine / chemokine secretion (IGRA-specific and purified protein derivate (PPD) –specific) titres in association with the time since successful tuberculosis (TB) -treatment as an indicator of the IGRA reversion rate over time, taking into account possible confounders, in particular CD4 recovery rate and TB re-exposure risk.

Study Design:
Cohort study analysing the effect of time since TB-treatment on IGRA / PPD negativity rates in all HIV-infected patients enrolled in the SHCS with previous treatment for active TB.